BioIntel is now The Catalyst Brief.
The Catalyst Brief

More coverage

PharmaLogic Buys Lantheus Plant, Extending Its Radiopharmaceutical CDMO Reach Across The AtlanticBiopharmaceutical Industry

PharmaLogic Buys Lantheus Plant, Extending Its Radiopharmaceutical CDMO Reach Across The Atlantic

The assets came to Lantheus through its $250 million upfront acquisition of Evergreen Theragnostics last year, but are now being sold 19 months later. For PharmaLogic, the purchase adds a 14,000-square-foot facility with seven commercial-scale production suites and strengthens its claim to a transatlantic therapeutic CDMO platform.

The Catalyst BriefNov 14, 2026
Charles River Buys Two Frontage Labs For $470 Million, Expanding Clinical Bioanalysis CapacityBiopharmaceutical Industry

Charles River Buys Two Frontage Labs For $470 Million, Expanding Clinical Bioanalysis Capacity

The acquisition gives Charles River two Exton, Pennsylvania sites totaling 150,000 square feet and around 340 employees. For the CRO, the transaction is less about adding lab space than about tightening the handoff between preclinical and clinical testing as biologics and more complex modalities take a larger share of pipelines.

The Catalyst BriefNov 13, 2026
Windward Bio Hits $225 Million IPO Goal, Funding China-Licensed Respiratory ProgramsHealthcare Investment

Windward Bio Hits $225 Million IPO Goal, Funding China-Licensed Respiratory Programs

The Basel-based biotech sold 10.3 million shares at $17 apiece and could add around $26.2 million more if underwriters exercise their option for another 1.5 million shares. The raise is aimed primarily at WIN378 in COPD and asthma, with additional capital earmarked for the dual-targeting WIN027 and earlier bispecific work.

The Catalyst BriefNov 13, 2026
Regeneron Posts Positive Phase 2 Baloncibart Data In POTS, Setting Up A 2027 Phase 3 TrialBiotech Innovation

Regeneron Posts Positive Phase 2 Baloncibart Data In POTS, Setting Up A 2027 Phase 3 Trial

In the 82-patient Pinnacle study, a single 450 mg dose reduced the change in heart rate from lying down to standing by 11.4 beats per minute versus placebo at Day 8 and by 7.4 beats per minute at Day 29. The signal was weaker at 150 mg, while adverse events were more common on treatment but were mostly mild or moderate and did not lead to discontinuations.

The Catalyst BriefNov 13, 2026
Bristol Myers Squibb Reorganizes R&D, With Robert Plenge Departing Amid Patent-Loss PressureBiopharmaceutical Industry

Bristol Myers Squibb Reorganizes R&D, With Robert Plenge Departing Amid Patent-Loss Pressure

Bristol Myers Squibb said its R&D reorganization is meant to connect scientific and clinical expertise more closely and sharpen portfolio execution. Chief Research Officer Robert Plenge will leave by the end of the year, while Cristian Massacesi will take charge of the unified organization at the start of next year.

The Catalyst BriefNov 13, 2026
Vor Pays RemeGen $10 Million Upfront For RC298, Extending BAFF/APRIL Autoimmune BetBiopharmaceutical Industry

Vor Pays RemeGen $10 Million Upfront For RC298, Extending BAFF/APRIL Autoimmune Bet

The transaction shows Vor is building depth around one autoimmune mechanism rather than broadening into unrelated assets. It also suggests the company sees dosing convenience as a commercial and clinical differentiator worth buying before human data are available outside the existing franchise context.

The Catalyst BriefNov 13, 2026
ARPA-H Backs Ibogaine With Up To $4.9 Million, Expanding Federal Psychedelic Focus Beyond PsilocybinRegulatory & Policy

ARPA-H Backs Ibogaine With Up To $4.9 Million, Expanding Federal Psychedelic Focus Beyond Psilocybin

The funding announcement signals a broader government effort to test multiple psychotropic approaches rather than rely on a single development path. It also places ibogaine, a substance with a more unconventional clinical profile than better-known psychedelic candidates, inside a federal program aimed at generating IND-ready evidence across more than one indication.

The Catalyst BriefNov 13, 2026
FDA Appears To Pause CNPV Reviews And CRL Disclosures, Leaving Makary-Era Reforms In LimboRegulatory & Policy

FDA Appears To Pause CNPV Reviews And CRL Disclosures, Leaving Makary-Era Reforms In Limbo

Reuters, as cited by Fierce Biotech, reported that the FDA has quietly shelved the Commissioner’s National Priority Voucher pilot for new awards, even as the agency says work under the program is ongoing for applications that already received a voucher. At the same time, the FDA has not added a new complete response letter to its public database for the past three months, despite saying it remains committed to publishing appropriately redacted letters.

The Catalyst BriefNov 12, 2026
Neurosterix Raises $105 Million Series B, Funding A Planned Phase 2 Schizophrenia TrialHealthcare Investment

Neurosterix Raises $105 Million Series B, Funding A Planned Phase 2 Schizophrenia Trial

Addex Therapeutics’ neuropsychiatric spinout said the new financing will primarily support NTX-253, an oral muscarinic M4 positive allosteric modulator being prepared for phase 2 in schizophrenia. The deal also offers a read on where investors still see fundable differentiation in CNS: assets that promise efficacy without the movement disorders and metabolic complications associated with traditional dopamine antagonists.

The Catalyst BriefNov 12, 2026
Pfizer Secures Up To $1.5 Billion From Blackstone, Offsetting Berobenatide Development Costs Through 2028Biopharmaceutical Industry

Pfizer Secures Up To $1.5 Billion From Blackstone, Offsetting Berobenatide Development Costs Through 2028

The agreement centers on berobenatide, Pfizer’s monthly GLP-1 receptor agonist acquired in the $9.8 billion Metsera takeover. As Pfizer runs a 10-trial phase 3 program and targets a 2028 launch, the financing offers a way to preserve flexibility ahead of key patent expirations while keeping upside tied to U.S. approval and sales milestones.

The Catalyst BriefNov 12, 2026
Amgen Posts 70.5% STAR Response For Dazodalibep In Sjögren’s, Setting Up A Novartis MatchupBiopharmaceutical Industry

Amgen Posts 70.5% STAR Response For Dazodalibep In Sjögren’s, Setting Up A Novartis Matchup

Amgen’s latest presentation on dazodalibep gives investors a clearer look at how broad the phase 3 benefit may be in systemic Sjögren’s disease. The immediate significance is not only the strength of the placebo-adjusted effect, but how directly the data invite comparison with Novartis as the field moves toward a multi-product market rather than a single-winner launch.

The Catalyst BriefNov 12, 2026

Join The Catalyst Brief newsletter

Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy delivered to your inbox.

Free, no spam. Unsubscribe anytime.